98%
921
2 minutes
20
Purpose: The optimal treatment approach for submacular hemorrhage (SMH) secondary to idiopathic polypoid choroidal vasculopathy (IPCV) remains uncertain. This study aimed to explore the prognosis and complications of pars plana vitrectomy (PPV) followed by subretinal or intravitreal injection with Conbercept (0.05 ml, 10 mg/ml) and tissue plasminogen activator (t-PA) (0.05 ml ~ 0.1 ml, 0.25 mg/ml) for submacular hemorrhage (SMH) secondary to IPCV.
Methods: This retrospective study included patients with SMH secondary to IPCV who received PPV followed by subretinal or intravitreal injection with Conbercept and t-PA at the Affiliated Eye Hospital of Nanchang University between March and November 2023. The rate of SMH clearance, best corrected visual acuity (BCVA), and central macular thickness (CMT), and postoperative complications at 1 week, 1 month, 3 months and 6 months post-treatment were collected.
Results: A total of 41 patients were included, with 22 (8 males, 14 left eyes) of who received subretinal injection.Patients who received subretinal injection showed significantly less times of injections (P = 0.008), compared with those received intravitreal injection. Repeated measurement analysis showed that, compared with intravitreal injection, patients who received subretinal injection exhibited significant higher SMH clearance ratio (P < 0.001), while comparable BCVA (P = 0.942) and CMT (0.906). In addition, the occurrence of postoperative complications, including vitreous hemorrhage (P = 0.999) and macular hemorrhage (P = 0.463), between those received subretinal and intravitreal injection were similar.
Conclusion: Compared with intravitreal injection, PPV followed by subretinal injection with Conbercept and t-PA might be a more optimal protocol with higher SMH clearance ratio for SMH Secondary to IPCV.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10792-025-03642-y | DOI Listing |
Eye (Lond)
September 2025
Kim's Eye Hospital, Konyang University College of Medicine, Seoul, South Korea.
Objective: To compare the effectiveness of intravitreal faricimab and aflibercept injections in patients with polypoidal choroidal vasculopathy (PCV).
Methods: This retrospective study analysed 111 treatment-naïve eyes (111 patients) with PCV who received intravitreal injections of either faricimab (30 eyes) or aflibercept (81 eyes). All patients were treated with three initial monthly loading injections.
ACS Appl Mater Interfaces
September 2025
School of Science, RMIT University, P.O. Box 2476, Melbourne 3001, Australia.
Lutein is a plant pigment beneficial for eye health and for preventing retinal-related diseases. However, lutein is unstable, with low oral bioavailability. In this study, lutein fromwas loaded into cubosome lipid nanocarriers, both neutral (lutein-MO) and cationic (lutein-MO-DOTAP); the release, stability, and retinal penetration of the drug were improved.
View Article and Find Full Text PDFPurpose: To assess how transitioning from an Aflibercept to a Faricimab intravitreal treatment impacts retinal structures and functional aspects in patients with neovascular age related macular degeneration (nAMD) in a real-life setting.
Patients And Methods: A retrospective clinical study including 49 patients (57 eyes) with nAMD at the Department of Ophthalmology and Optometry, Kepler University Hospital, Linz, Austria was performed. The patients, who had previously been receiving monthly Aflibercept injections with an unsatisfactory treatment response, were switched to intravitreal Faricimab and followed-up between 12/2022 and 12/2023.
Vestn Oftalmol
September 2025
OOO Prostranstvo intellektual'nykh reshenij, Novorossiysk, Russia.
Unlabelled: Automated analysis of optical coherence tomography (OCT) biomarkers improves the prediction of results of loading anti-VEGF therapy of vascular pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nAMD).
Objective: This study evaluated the effectiveness of OCT biomarker analysis algorithm in predicting the anatomical outcomes of loading anti-VEGF therapy for vascular PED in nAMD.
Material And Methods: OCT scans performed prior to loading anti-VEGF therapy were analyzed using the algorithm in 69 treatment-naïve nAMD patients (70 eyes) with vascular PED exceeding 200 µm in height.